MCID: CRB088
MIFTS: 38

Cerebral Atrophy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Cerebral Atrophy

MalaCards integrated aliases for Cerebral Atrophy:

Name: Cerebral Atrophy 50 28 69

Classifications:



External Ids:

UMLS 69 C0235946

Summaries for Cerebral Atrophy

NINDS : 50 Cerebral atrophy is a common feature of many of the diseases that affect the brain. Atrophy of any tissue means loss of cells. In brain tissue, atrophy describes a loss of neurons and the connections between them. Atrophy can be generalized, which means that all of the brain has shrunk; or it can be focal, affecting only a limited area of the brain and resulting in a decrease of the functions that area of the brain controls. If the cerebral hemispheres (the two lobes of the brain that form the cerebrum) are affected, conscious thought and voluntary processes may be impaired. Associated Diseases/Disorders: The pattern and rate of progression of cerebral atrophy depends on the disease involved. Diseases that cause cerebral atrophy include: stroke and traumatic brain injury Alzheimer’s disease, Pick’s disease, and fronto-temporal dementia cerebral palsy, in which lesions (damaged areas) may impair motor coordination Huntington’s disease, and other hereditary diseases that are associated with genetic mutations leukodystrophies, such as Krabbe disease, which destroy the myelin sheath that protects axons mitochondrial encephalomyopathies, such as Kearns-Sayre syndrome, which interfere with the basic functions of neurons multiple sclerosis, which causes inflammation, myelin damage, and lesions in cerebral tissue infectious diseases, such as encephalitis, neurosyphilis, and AIDS, in which an infectious agent or the inflammatory reaction to it destroys neurons and their axons Symptoms of cerebral atrophy: Many diseases that cause cerebral atrophy are associated with dementia, seizures, and a group of language disorders called the aphasias.  Dementia is characterized by a progressive impairment of memory and intellectual function that is severe enough to interfere with social and work skills. Memory, orientation, abstraction, ability to learn, visual-spatial perception, and higher executive functions such as planning, organizing, and sequencing may also be impaired. Seizures can take different forms, appearing as disorientation, repetitive movements, loss of consciousness, or convulsions. Aphasias are a group of disorders characterized by disturbances in speaking and understanding language. Receptive aphasia causes impaired comprehension. Expressive aphasia is reflected in odd choices of words, the use of partial phrases, disjointed clauses, and incomplete sentences.

MalaCards based summary : Cerebral Atrophy is related to aicardi-goutieres syndrome and keratosis follicularis, dwarfism, and cerebral atrophy, and has symptoms including headache An important gene associated with Cerebral Atrophy is VPS53 (VPS53, GARP Complex Subunit). The drugs Interferon beta-1a and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and kidney, and related phenotypes are mortality/aging and skeleton

Wikipedia : 72 Cerebral atrophy is a common feature of many of the diseases that affect the brain.Atrophy of any tissue... more...

Related Diseases for Cerebral Atrophy

Diseases in the Cerebral Atrophy family:

Autosomal Recessive Cerebral Atrophy

Diseases related to Cerebral Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 aicardi-goutieres syndrome 30.4 ADAR RNASEH2B
2 keratosis follicularis, dwarfism, and cerebral atrophy 12.3
3 autosomal recessive cerebral atrophy 11.9
4 prieto x-linked mental retardation syndrome 11.6
5 pontocerebellar hypoplasia, type 2e 11.5
6 incontinentia pigmenti 11.1
7 pontocerebellar hypoplasia, type 2a 11.0
8 epileptic encephalopathy, early infantile, 17 10.9
9 aicardi-goutieres syndrome 7 10.9
10 aicardi-goutieres syndrome 1 10.9
11 aicardi-goutieres syndrome 3 10.9
12 neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination 10.9
13 neurodevelopmental disorder with involuntary movements 10.9
14 encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities 10.9
15 asparagine synthetase deficiency 10.9
16 pontocerebellar hypoplasia, type 2d 10.9
17 cerebritis 10.8
18 ceroid lipofuscinosis, neuronal, 6 10.8
19 neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant 10.8
20 aicardi-goutieres syndrome 6 10.8
21 encephalopathy, familial, with neuroserpin inclusion bodies 10.8
22 ceroid lipofuscinosis, neuronal, 3 10.8
23 ceroid lipofuscinosis, neuronal, 4a, autosomal recessive 10.8
24 mohr-tranebjaerg syndrome 10.8
25 ceroid lipofuscinosis, neuronal, 2 10.8
26 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.8
27 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.8
28 ceroid lipofuscinosis, neuronal, 10 10.8
29 aicardi-goutieres syndrome 2 10.8
30 3-methylglutaconic aciduria, type viii 10.8
31 galloway-mowat syndrome 1 10.8
32 neurodevelopmental disorder with hypotonia, seizures, and absent language 10.8
33 cerebellum agenesis hydrocephaly 10.8
34 ceroid lipofuscinosis, neuronal, 4b, autosomal dominant 10.8
35 ceroid lipofuscinosis, neuronal, 1 10.8
36 ceroid lipofuscinosis, neuronal, 8 10.8
37 epileptic encephalopathy, early infantile, 51 10.8
38 ceroid lipofuscinosis, neuronal, 5 10.8
39 aicardi-goutieres syndrome 4 10.8
40 oculopalatocerebral syndrome 10.8
41 ceroid lipofuscinosis, neuronal, 7 10.8
42 peho syndrome 10.8
43 aicardi-goutieres syndrome 5 10.8
44 dementia 10.3
45 aging 10.2
46 multiple sclerosis 10.2
47 alzheimer disease 10.2
48 hydrocephalus 10.1
49 schizophrenia 10.1
50 brain injury 10.0

Graphical network of the top 20 diseases related to Cerebral Atrophy:



Diseases related to Cerebral Atrophy

Symptoms & Phenotypes for Cerebral Atrophy

UMLS symptoms related to Cerebral Atrophy:


headache

MGI Mouse Phenotypes related to Cerebral Atrophy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.43 ADAR CLN6 GNAO1 HECW2 RNASEH2B VPS53
2 skeleton MP:0005390 8.92 ADAR CLN6 GNAO1 VPS53

Drugs & Therapeutics for Cerebral Atrophy

Drugs for Cerebral Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2 145258-61-3 6438354
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
5
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
6
Memantine Approved, Investigational Phase 4 19982-08-2 4054
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
9
Glatiramer Acetate Approved, Investigational Phase 4,Phase 1,Phase 2 147245-92-9 3081884
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Interferon beta-1b Approved Phase 4,Phase 2 145155-23-3
13
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
17 interferons Phase 4,Phase 3,Phase 2
18 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
19 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Excitatory Amino Acid Antagonists Phase 4,Phase 2
24 Excitatory Amino Acids Phase 4,Phase 2
25 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
26 Interferon-beta Phase 4,Phase 3,Phase 2
27 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Antirheumatic Agents Phase 4,Phase 1,Phase 2
29 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Prednisolone acetate Phase 4
31 Dexamethasone acetate Phase 4 1177-87-3
32 glucocorticoids Phase 4
33 Respiratory System Agents Phase 4,Phase 2
34 Methylprednisolone acetate Phase 4
35 Methylprednisolone Hemisuccinate Phase 4
36 Fingolimod Hydrochloride Phase 4,Phase 1,Phase 2
37 Folic Acid Antagonists Phase 4
38 N-monoacetylcystine Phase 4
39 Cholinergic Agents Phase 4,Phase 3
40 Cholinesterase Inhibitors Phase 4,Phase 3
41 Gastrointestinal Agents Phase 4
42 Nootropic Agents Phase 4,Phase 3
43 Nucleic Acid Synthesis Inhibitors Phase 4
44 Hormone Antagonists Phase 4,Phase 2
45 Dermatologic Agents Phase 4,Phase 3
46 Vitamin B Complex Phase 4,Phase 2,Phase 3
47 Hormones Phase 4,Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
49 Dopamine Agents Phase 4
50 Antibodies, Blocking Phase 4

Interventional clinical trials:

(show top 50) (show all 116)

# Name Status NCT ID Phase Drugs
1 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo
2 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4 memantine HCl
3 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
4 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
5 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
6 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
7 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4 Cystagon
8 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
9 The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT01921972 Phase 4 Galantamine CR;Memantine;Placebo
10 Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis Recruiting NCT03345940 Phase 4 Fingolimod;Dimethyl Fumarate
11 Effect of Fingolimod on Neurodegeneration Terminated NCT02575365 Phase 4 0,5 mg Fingolimod
12 Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate Terminated NCT00203047 Phase 4 Glatiramer Acetate;Placebo;Prednisone
13 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
14 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
15 IMaging Della PLAcca Carotidea Completed NCT03333330 Phase 3 Visipaque 320 and SonoVue
16 Magnetic Stimulation Therapy for Treating Vascular Depression Completed NCT00044798 Phase 3 Citalopram
17 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed NCT00236574 Phase 3 Galantamine hydrobromide
18 Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3 Davunetide;Placebo
19 Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline Completed NCT00878631 Phase 2, Phase 3 hypertonic saline mixed with dextran;Normal Saline
20 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3 EGCG as putative neuroprotective agent;Placebo
21 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
22 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
23 Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease Completed NCT00951834 Phase 2, Phase 3 Epigallocatechin-Gallate;Placebo
24 Omega-3 Fatty Acid Treatment in Multiple Sclerosis Completed NCT00360906 Phase 2, Phase 3 Triomar™ (omega-3 fatty acids)
25 Brain Imaging and Safety Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease Recruiting NCT03446001 Phase 2, Phase 3 TRx0237 8 mg/day;Placebo
26 Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Recruiting NCT03122652 Phase 3 Teriflunomide 14 MG Oral Tablet [Aubagio];Placebo Oral Tablet
27 National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Ph Active, not recruiting NCT02937285 Phase 3 Interferon beta 1a;Mitoxantrone
28 Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Active, not recruiting NCT02201108 Phase 3 Teriflunomide HMR1726;Placebo
29 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) Active, not recruiting NCT00835770 Phase 3 dimethyl fumarate;Placebo
30 Multiple Sclerosis-Simvastatin Trial 2 Not yet recruiting NCT03387670 Phase 3 Simvastatin;Placebo
31 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
32 Phase 3 IGIV, 10% in Alzheimer´s Disease Terminated NCT01524887 Phase 3
33 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
34 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
35 A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis Unknown status NCT00217295 Phase 2 Avonex and Topamax
36 The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis Unknown status NCT00917839 Phase 2 lamotrigine
37 Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination Unknown status NCT01627938 Phase 2 Dexrazoxane (DRZ) plus Mitoxantrone (MX);Placebo plus Mitoxantrone (MX)
38 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
39 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
40 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo
41 Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) Completed NCT00525668 Phase 1, Phase 2 epigallocatechin-gallate (Sunphenon);placebo
42 Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation Completed NCT00342381 Phase 2 3,4-diaminopyridine;Placebo
43 Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b Completed NCT00942591 Phase 2 Interferon beta 1b;Atorvastatin
44 Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis Completed NCT01377870 Phase 1, Phase 2
45 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
46 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b Completed NCT01111656 Phase 2 Interferon beta-1b group;Interferon beta-1b/Atorvastatin group
47 Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) Completed NCT01357681 Phase 2 (2)-epigallocatechin-3-gallate (EGCG);Placebo
48 Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients Recruiting NCT02085265 Phase 2 Perindopril;Telmisartan
49 Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) Recruiting NCT03022968 Phase 2 [18F]T807 PET
50 Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome Active, not recruiting NCT03300453 Phase 1, Phase 2 rAAV2/5-hNAGLU

Search NIH Clinical Center for Cerebral Atrophy

Genetic Tests for Cerebral Atrophy

Genetic tests related to Cerebral Atrophy:

# Genetic test Affiliating Genes
1 Cerebral Atrophy 28

Anatomical Context for Cerebral Atrophy

MalaCards organs/tissues related to Cerebral Atrophy:

38
Brain, Testes, Kidney, Retina, Temporal Lobe, Pineal, Liver

Publications for Cerebral Atrophy

Articles related to Cerebral Atrophy:

(show top 50) (show all 406)
# Title Authors Year
1
Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities. ( 29314393 )
2018
2
A novel TRAPPC11 mutation in two Turkish families associated with cerebral atrophy, global retardation, scoliosis, achalasia and alacrima. ( 27707803 )
2017
3
Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma. ( 28182114 )
2017
4
White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not. ( 28629404 )
2017
5
Blood Pressure Control in Aging Predicts Cerebral Atrophy Related to Small-Vessel White Matter Lesions. ( 28555103 )
2017
6
Cockayne syndrome with intracranial calcification, hypomyelination, and cerebral atrophy. ( 28149095 )
2017
7
Interferon-I^ Is Associated with Cerebral Atrophy in Systemic Lupus Erythematosus. ( 28848179 )
2017
8
Association of White Matter Lesions, Cerebral Atrophy, Intracranial Extravascular Calcifications, and Ventricular-Communicating Hydrocephalus with Delirium Among Veterans. ( 28575905 )
2017
9
Reversible Cerebral Atrophy in Infantile Tremor Syndrome. ( 27395831 )
2016
10
Impaired fasting blood glucose is associated to cognitive impairment and cerebral atrophy in middle-aged non-human primates. ( 28039490 )
2016
11
Does Side of Onset Influence the Pattern of Cerebral Atrophy in Parkinson's Disease? ( 27672378 )
2016
12
Pontine and cerebral atrophy in Lennox-Gastaut syndrome. ( 26808205 )
2016
13
On aA remarkable syndrome of cerebral atrophy associated with hyperammonaemia in childhood. ( 27577062 )
2016
14
Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysis. ( 27239527 )
2015
15
Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. ( 26239178 )
2015
16
Progressive cerebral atrophy in neuromyelitis optica. ( 26359279 )
2015
17
Retinal neurodegeneration on optical coherence tomography and cerebral atrophy. ( 25451722 )
2015
18
Parry-Romberg syndrome associated with contralateral cerebral atrophy. ( 26771367 )
2015
19
Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. ( 25990306 )
2015
20
Long-Term Migration of a Deep Brain Stimulation (DBS) Lead in the Third Ventricle Caused by Cerebral Atrophy in a Patient with Anterior Thalamic Nucleus DBS. ( 26819942 )
2015
21
Cerebral atrophy is linked to clinical severity and worsens with aging in patients with Pelizaeus-Merzbacher disease and Spastic Paraplegia type 2. ( 26531569 )
2015
22
Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors. ( 25523616 )
2015
23
Retraction. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008 Dec;131(Pt 12):3311a8934. doi:10.1093/brain/awn288. ( 24860127 )
2014
24
Cerebral atrophy and subdural haemorrhage after cerebellar and cerebral infarcts in an 8-month-old child after having been stung by a scorpion. ( 24962491 )
2014
25
Cerebral atrophy in a vitamin B12-deficient infant of a vegetarian mother. ( 25076673 )
2014
26
Evolution of a symptomatic diffuse developmental venous anomaly with progressive cerebral atrophy in an atypical case of Sturge-Weber syndrome. ( 25547041 )
2014
27
Cerebral atrophy and dementia in type 2 diabetes mellitus: report of two cases and review of literature. ( 24956625 )
2014
28
VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). ( 24577744 )
2014
29
Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy. ( 24045571 )
2014
30
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy. ( 24515696 )
2014
31
Subdural hemorrhages associated with antithrombotic therapy in infants with cerebral atrophy. ( 25113301 )
2014
32
Association of SORL1 gene variants with hippocampal and cerebral atrophy and Alzheimer's disease. ( 24938503 )
2014
33
An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. ( 25516199 )
2014
34
Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: a positron emission tomography study corrected for cerebral atrophy. ( 24098376 )
2013
35
Cerebral atrophy in elderly with subjective memory complaints. ( 23239111 )
2013
36
Methylglyoxal, cognitive function and cerebral atrophy in older people. ( 22496536 )
2013
37
Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome. ( 22890637 )
2013
38
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. ( 23303849 )
2013
39
Cerebral atrophy is an independent risk factor for unfavorable outcome after spontaneous supratentorial intracerebral hemorrhage. ( 23412376 )
2013
40
Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage. ( 23662822 )
2013
41
P-selectin Expression Tracks Cerebral Atrophy in Mexican-Americans. ( 22558002 )
2012
42
Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. ( 21596458 )
2012
43
How much do focal infarcts distort white matter lesions and global cerebral atrophy measures?. ( 23154746 )
2012
44
Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments. ( 20970891 )
2012
45
Cerebral atrophy is associated with development of chronic subdural haematoma. ( 22759238 )
2012
46
Age-associated cerebral atrophy in mouse lemur primates. ( 19564059 )
2011
47
Functional abnormalities and cerebral atrophy in posttraumatic stress disorder and dementia: is there a causal link between the two diseases? ( 21314666 )
2011
48
I^-Amyloid (1-42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. ( 22187546 )
2011
49
Rapid progressive cerebral atrophy in systemic lupus erythematosus. ( 22134797 )
2011
50
Intracranial air correlates with preoperative cerebral atrophy and stereotactic error during bilateral STN DBS surgery for Parkinson's disease. ( 21778795 )
2011

Variations for Cerebral Atrophy

Expression for Cerebral Atrophy

Search GEO for disease gene expression data for Cerebral Atrophy.

Pathways for Cerebral Atrophy

GO Terms for Cerebral Atrophy

Biological processes related to Cerebral Atrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 8.62 ADAR RNASEH2B

Sources for Cerebral Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....